QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

First published online 1 June 2004
doi: 10.1242/jcs.01147

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jcs.01147v1 117/14/3061    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Turner, J. G. Articles by Sullivan, D. M. Search for Related Content PubMed PubMed Citation Articles by Turner, J. G. Articles by Sullivan, D. M.

Human topoisomerase II nuclear export is mediated by two CRM-1-dependent nuclear export signals

Joel G. Turner^1,*, Roxanne Engel^1,*, Jennifer A. Derderian¹, Richard Jove² and Daniel M. Sullivan^1,

¹ Experimental Therapeutics, Departments of Interdisciplinary Oncology and Biochemistry and Molecular Biology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
² Molecular Oncology Programs, Departments of Interdisciplinary Oncology and Biochemistry and Molecular Biology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA

Author for correspondence (e-mail: sullivad{at}moffitt.usf.edu)

Accepted 9 February 2004

Resistance to chemotherapeutic drugs is a major obstacle in the treatment of leukemia and multiple myeloma. We have previously found that myeloma and leukemic cells in transition from low-density log phase conditions to high-density plateau phase conditions export substantial amounts of endogenous topoisomerase II alpha from the nucleus to the cytoplasm. In order for topoisomerase-targeted chemotherapy to function, the topoisomerase target must have access to the nuclear DNA. Therefore, the nuclear export of topoisomerase II alpha may contribute to drug resistance, and defining this mechanism may lead to methods to preclude this avenue of resistance. We have identified nuclear export signals for topoisomerase II alpha at amino acids 1017-1028 and 1054-1066, using FITC-labeled BSA-export signal peptide conjugates microinjected into the nuclei of HeLa cells. Functional confirmation of both signals (1017-1028 and 1054-1066) was provided by transfection of human myeloma cells with plasmids containing the gene for a full-length human FLAG-topoisomerase fusion protein, mutated at hydrophobic amino acid residues in the export signals. Of the six putative export signals tested, the two sites above were found to induce export into the cytoplasm. Export by both signals was blocked by treatment of the cells with leptomycin B, indicating that a CRM-1-dependent pathway mediates export. Site-directed mutagenesis of two central hydrophobic residues in either export signal in full-length human topoisomerase blocked export of recombinant FLAG-topoisomerase II alpha, indicating that both signals may be required for export. Interestingly, this pair of nuclear export signals (1017-1028 and 1054-1066) also defines a dimerization domain of the topoisomerase II alpha molecule.

Key words: Topoisomerase II alpha (topo II), Nuclear export signal (NES), CRM-1, Site-directed mutagenesis, Microinjection

This article has been cited by other articles:

				A. Di Leo and E. Moretti Anthracyclines: The First Generation of Cytotoxic Targeted Agents? A Possible Dream J. Clin. Oncol., November 1, 2008; 26(31): 5011 - 5013. [Full Text] [PDF]

				J. P. Wyles, Z. Wu, S. E.L. Mirski, and S. P.C. Cole Nuclear interactions of topoisomerase II {alpha} and {beta} with phospholipid scramblase 1 Nucleic Acids Res., June 12, 2007; (2007) gkm434v1. [Abstract] [Full Text] [PDF]

				J. G. Turner, J. L. Gump, C. Zhang, J. M. Cook, D. Marchion, L. Hazlehurst, P. Munster, M. J. Schell, W. S. Dalton, and D. M. Sullivan ABCG2 expression, function, and promoter methylation in human multiple myeloma Blood, December 1, 2006; 108(12): 3881 - 3889. [Abstract] [Full Text] [PDF]